Member Info for AI-Research

Looking amazing now guys

Strategic Partnerships: The company is in active discussions with major distributors for test distribution in both the U.S. and EU, which could significantly accelerate commercial scaling once approved.

https://share.google/aimode/J2h49hwmNVzWtqwL9

Analysts maintain a Strong Buy consensus for Genincode (GENI.L) as of February 2026, with 12-month price targets ranging from 7.50p to 11.50p. These targets represent a significant potential upside of over 500% from recent trading levels near 1.15p.

The positive outlook is primarily driven by the company's progress toward U.S. FDA De Novo classification for its CARDIO inCode-Score test, with final data submission expected in Q1 2026.

Analyst Price Targets & Ratings

Based on current analyst coverage as of February 2026:

Consensus Rating: Strong Buy.

Average Price Target: 7.50p.

High Price Target: 11.50p.

Low Price Target: 7.50p.

Implied Upside: Approximately 535% to 614% based on a share price of ~1.15p.

Key Insights for 2026

U.S. Regulatory Catalyst: Genincode is addressing FDA "deficiencies" for its CARDIO inCode-Score test. A successful Q1 2026 data submission could unlock a U.S. market estimated at $10.5 billion.

Cash Runway: The company recently completed a £4.7 million fundraising (at a discount) to extend its cash runway through the U.S. regulatory process. Previous estimates suggested cash would last into Q1 2026.

Revenue Pressures: Full-year 2025 revenue guidance was lowered to £3.3m (from higher previous estimates) due to NHS restructuring and FDA delays.

Strategic Partnerships: The company is in active discussions with major distributors for test distribution in both the U.S. and EU, which could significantly accelerate commercial scaling once approved.

GENinCode Plc is generating cost savings for the NHS through its genomic testing portfolio, which focuses on cardiovascular disease (CVD) and, more recently, ovarian cancer surveillance.

Key information regarding GENinCode's economic impact on the NHS:

Cost Efficiency: The cost of GENinCode testing is approximately half that of standard NHS costs for similar assessments, providing a more comprehensive cardiovascular disease prevention assessment.

Ovarian Cancer (ROCA): The Risk of Ovarian Cancer Algorithm (ROCA) test has been adopted by University College London Hospitals NHS Foundation Trust (UCLH). Economic analysis indicates that the ROCA test can reduce late-stage ovarian cancer detections by 44%, offering significant cost savings to the NHS.

Cardiovascular Savings: GENinCode’s tests (including LIPID inCode® and CARDIO inCode®) assist the NHS in identifying high-risk individuals for CVD, supporting the NHS 10-Year Plan by offering preventative, cost-saving measures for heart disease.

Expansion: The NHS has expanded the use of LIPID inCode® for familial hypercholesterolemia (FH) diagnosis in the North of England.

The company's technology aids in reducing the overall burden on NHS resources by enabling earlier, more accurate diagnoses, thus shifting from costly reactive treatment to lower-cost preventative care.

Will not stay here into April going high

Https://x.com/AfzalValli/status/2028819002990960902?s=20

Conversations with a $50 billion healthcare company Haleon 👇

The Company and Cooper Consumer Health are undertaking a commercial review with regards to the most appropriate market models in the EU. Additionally, the Company is in conversations with Haleon relating to alternative, potentially third party, commercial and distribution strategies and arrangements.

Buyers are pummeling this afternoon we have always been leaky 5p+

Faron Pharmaceuticals Ltd | Press Release | March 02, 2026 at 09:00:00 EET

https://faron.com/releases-and-publications/faron-and-city-of-hope-in-process-of-developing-a-phase-ii-investigator-initiated-trial-of-bexmarilimab-in-relapsed-refractory-mds/

Building on the clinical results of the BEXMAB trial, the IIT aims to evaluate bexmarilimab with an oral HMA backbone to further strengthen evidence of its efficacy in research participants with high-risk myelodysplastic syndrome (HR MDS)

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer, today announces that investigators at City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, are in the process of developing a Phase II investigator-initiated clinical trial (IIT) in collaboration with Faron to evaluate bexmarilimab in participants with relapsed or refractory myelodysplastic syndrome (r/r MDS).

Https://share.google/aimode/8NcmQ2l3sOS1Y6cOR

Analysts covering Cellbxhealth PLC (CLBX) have a wide-ranging 12-month median share price target of approximately 17.00p (based on Investors' Chronicle and Stockopedia), which suggests a potential upside of over 1,500% from recent prices, with high estimates reaching up to 30.00p and lows around 4.00p. Other sources indicate a more conservative average target of 7.00p, still representing a high, bullish consensus.

Key analyst details and forecasts for Cellbxhealth (CLBX):

Consensus Rating: The stock is considered a "Strong Buy" based on available analyst projections.

Target Price Range: Projections range from a low of 4.00p to a high of 30.00p.

Recent Performance: As of late February 2026, the share price has been trading around 1.05p, having significantly underperformed the index.

Earnings & Outlook: Analysts have a consensus EPS forecast of -£0.04 for the coming financial year. While revenue is expected to grow, the company is still forecast to make losses in the near term.

Analysts maintain a Strong Buy consensus for Genincode (GENI.L) as of February 2026, with 12-month price targets ranging from 7.50p to 11.50p. These targets represent a significant potential upside of over 500% from recent trading levels near 1.15p.

The positive outlook is primarily driven by the company's progress toward U.S. FDA De Novo classification for its CARDIO inCode-Score test, with final data submission expected in Q1 2026

Analyst Price Targets & Ratings

Based on current analyst coverage as of February 2026:

Consensus Rating: Strong Buy.

Average Price Target: 7.50p.

High Price Target: 11.50p.

Low Price Target: 7.50p.

Implied Upside: Approximately 535% to 614% based on a share price of ~1.15p.

Strategic Partnerships: The company is in active discussions with major distributors for test distribution in both the U.S. and EU, which could significantly accelerate commercial scaling once approved.

U.S. Regulatory Catalyst: Genincode is addressing FDA "deficiencies" for its CARDIO inCode-Score test. A successful Q1 2026 data submission could unlock a U.S. market estimated at $10.5 billion.

Https://share.google/aimode/OINkZnvgGs8VqUcnb

PYX Resources (LSE: PYX) is currently transitioning to resume operations in 2026 following a 2025 suspension caused by Indonesian regulatory shifts. As of 27 February 2026, the share price closed at 0.2875 GBX, representing a 23.76% increase from the previous close.

Reports indicate the company has recently secured the necessary 2026 RKAB (Work Plan and Budget) permits required to restart its mineral sands operations in Central Kalimantan.

2026 Operational Outlook

The company’s ability to return to full production is the primary focus for 2026.

Permit Status: After operations at the Mandiri and Tisma deposits were halted in September 2025 due to the suspension of the annual RKAB system, PYX has reportedly received its 2026 approvals as part of a broader government reinstatement for major miners.

Production Targets: PYX is the world’s 3rd largest publicly listed zircon producer by resources, with 10.5 Mt of inferred resources. In the first half of 2025, production was 0 tonnes due to the suspension, compared to 4,500 tonnes in the same period of 2024.

Zircon Market: Premium Grade zircon prices are averaging US$2,150 per tonne as of February 2026, roughly 8% higher than 2025 levels.

Consensus Recommendation: Strong Buy.

Fair Value Estimate: WH Ireland previously published a fair value estimate of 82p per share based on discounted cash flow (DCF) models of combined Mandiri and Tisma operations.

Valuation Basis: The revised valuation used a mixed basis, averaging

and a peer multiple EV/EBITDA of 4x.

Factors: The valuation took into account high-margin premium zircon production and a conservative view on development pace.

As of 26 February 2026, the 12-month analyst consensus price target for PYX Resources (PYX) is 67.49p. This consensus is currently derived from a single analyst offering a forecast for the next year.

Analyst Targets and Ratings

Current analyst sentiment reflects a significant divergence between long-term valuation models and recent market performance.

Consensus Price Target (LSE): 67.49p, representing a massive theoretical upside from the current trading price of approximately 0.25p – 0.27p.

Secondary Broker Target: Some investor discussions note a secondary broker target of 185p, though this is considered highly speculative by market participants.

Consensus Recommendation: Strong Buy.

Fair Value Estimate: WH Ireland previously published a fair value estimate of 82p per share based on discounted cash flow (DCF) models of combined Mandiri and Tisma operations.

Key Insights

Performance Gap: Despite trading near a 52-week low of 0.21p, high analyst targets are driven by long-term valuations of zircon resources rather than short-term momentum.

Operational Status: While market speculation suggested potential 2026 RKAB permit approvals in late February, no official RNS announcement was released by 26 February 2026.

Market Trends: Positive catalysts include rising zircon prices, which averaged US$2,150 per tonne in February 2026.

Investor Calendar: The next earnings report is scheduled for 12 March 2026.

As of late February 2026, Sealand Capital Galaxy Ltd (LSE: SCGL) is trading at a very low share price, generally around 0.35p to 0.40p. There is limited, conflicting analyst coverage on a specific 12-month target price, with some projections suggesting a long-term range between 1.72 GBX and 3.58 GBX by 2026

Key Data Points (as of February 2026):

Current Price: Approximately 0.35p - 0.38p.

52-Week Range: 0.25p - 3.40p.

Market Capitalisation: ~£3.37 million - £3.79 million.

Core Operations & Business Segments

The company bridges global innovation with the digital markets of Emerging Asia, particularly the APAC region. It operates through two primary segments:

Digital Marketing and Payment: Includes enlisting merchants to mobile payment gateways (like WeChat Pay) and providing digital advertising services.

e-Commerce: Sales of goods via the internet and consultancy services. This segment generates the majority of the group's revenue, often focused on bringing international brands to the Chinese market.

Strategic Evolution & Key Brands

Sealand recently announced a strategic shift toward Artificial Intelligence (AI) and transformative tech

EVOO AI: Their flagship AI investment, which operates the Olive platform—an AI-driven luxury e-commerce marketplace featuring influencer-curated boutiques.

England Pie: A multi-brand beauty platform for niche European beauty brands in China, Hong Kong, and Macau.

ePurse: A cross-border solution connecting international merchants with Chinese consumers through WeChat services.

Corporate & Financial Snapshot

Leadership: Recently appointed Dr. Tom Sawyer as CEO (January 2025) and Peng Terng as CFO (January 2026).

Listing History: Incorporated in May 2015 and admitted to the LSE on 17 November 2015.

Market Position: As of February 2026, the company has a market capitalisation of approximately £3.21M – £3.79M. Its current share price fluctuates around 0.36p.

Revenue Source: Geographically, the majority of revenue is derived from Hong Kong operations.

At mid price will pop when filled

Still not filled now i know why

As of 26 February 2026, the 12-month analyst consensus price target for PYX Resources (PYX) is 67.49p. This suggests an extreme theoretical upside from the current trading price of 0.266p.

https://share.google/aimode/K0drvmXjeUbDWSZAk

A secondary broker target of 185p has also been noted in investor discussions, though this is considered highly speculative by market participants given the current valuation.

Key Financial Insights

Performance Gap: There is a massive divergence between the current share price (near a 52-week low of 0.21p) and analyst targets, which are primarily based on long-term valuation models of the company's zircon resources rather than recent market momentum.

Operational Recovery: Reports as of late February 2026 indicate that PYX has secured its required 2026 RKAB (Work Plan and Budget) permits from the Indonesian government. These approvals are critical as they allow the company to resume production and export activities following significant regulatory disruptions in 2025.

Zircon Market: The company stands to benefit from a recovery in zircon prices, with premium grades averaging US$2,150 per tonne in February 2026, an 8% increase from 2025 levels.

Earnings Outlook: The next earnings report for PYX Resources is scheduled for 12 March 2026.

A £10 ($1,000p) target price for Faron Pharmaceuticals (FARN) has been set by H.C. Wainwright as of February 23, 2026, driven by a "de-risked development path" and strong efficacy data from their BEXMAB trial for blood cancer. While this represents a significant upside from current share prices (approximately 50p-60p), it highlights high analyst confidence in the company's immunotherapy, Bexmarilimab.

Key Details on Faron Pharmaceuticals (FARN) Stock:

Target Price: H.C. Wainwright reiterated a £10 ($1,000p) target in Feb 2026, representing a massive potential upside from the ~50p range.

As of February 2026, analysts maintain a Strong Buy consensus for Futura Medical PLC (FUM), with a target price of 30.00 GBX, implying a significant upside from the 1.18 GBX share price on February 25, 2026.

https://share.google/aimode/016DoLZbBElh3TnLd

Financial Outlook: Following a reported 349% revenue increase to £13.93 million in 2024, the company expects to exceed guidance for 2025.

Cash Position: Backed by a £3.4 million cash position and an anticipated US$2.5 million milestone payment from Haleon in H1 2026, the company's cash runway is expected to last through December 2026.

Catalysts: A strategic review is set for completion in Q1 2026, with results due in mid-April.

As of February 26, 2026, analyst targets for PYX Resources Limited (PYX) reflect a significant divergence between current market performance and long-term valuation models. While one consensus target suggests an extreme upside to 67.49p (UK) or AU$97.42 (Australia), the stock is currently trading at approximately 0.27p, near its 52-week low of 0.21p

https://share.google/aimode/g5XEPgHBO9AX9pbVc

Analyst Price Targets & Ratings

Analysts maintain a "Strong Buy" consensus, though this is primarily based on valuation models rather than recent momentum.

12-Month Price Target: The lone analyst providing a forecast expects the price to rise to 67.49p.

Consensus Recommendation: Strong Buy.

Key Financial Metrics (2025–2026)

Financial performance has been impacted by regulatory hurdles in Indonesia, though revenue growth was noted in earlier 2025 filings.

London Stock Exchange

London Stock Exchange

+2

Market Capitalisation: Approximately £1.12 million (UK listing) / AU$235.44 million (NSX listing).

52-Week Range: 0.21p – 3.01p.

Key Insights & Operational Outlook

Indonesian Permits (RKAB): Speculation is high regarding the renewal of the 2026 RKAB (Work Plan and Budget) permits for the Mandiri and Tisma deposits. While social media reports suggest approvals have been secured, there has been no official Regulatory News Service (RNS) announcement as of late February 2026.

Zircon Market: PYX stands to benefit from rising zircon prices, with premium grades averaging US$2,150 per tonne in February 2026, an 8% increase from 2025.

Production Capacity: Long-term models suggest that if PYX reaches its goal of 200ktpa zircon output by 2030, it could generate annual EBITDA exceeding US$200 million.

I have had it sitting for 2 full days

As of February 25, 2026, reports indicate that PYX Resources Limited has secured its required 2026 RKAB (Work Plan and Budget) permits for its mineral sands operations in Indonesia. These approvals allow the company to resume production and export activities following a period of significant regulatory disruption in 2025.

Key Permit Details

Permit Type: 2026 RKAB (Work Plan and Budget).

https://share.google/aimode/R396NFkSg7KyVUFS0